SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

Oral semaglutide (Rybelsus) can be tied to a near halving of incident Afib, according to a meta-analysis of 26 randomized ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

For patients newly diagnosed with atrial fibrillation during hospitalization for other causes, most are not dispensed anticoagulants in the year after discharge.

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

Three risk factors—high blood pressure, atrial fibrillation, and smoking—are more likely to cause severe strokes, meaning ...

Participants who walked faster were more likely to be men, live in less deprived areas, have healthier lifestyles and weigh ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...